Abstract 37P
Background
The "Hallmarks of Cancer" framework is foundational for understanding common organizational principles underlying diverse cancer types. However, the absence of a consensus gene set for cancer hallmarks leads to varied biological interpretations across studies. In this work, we established a unified cancer hallmark gene set by merging data from existing mapping resources and devising a framework for gene set mining.
Methods
We searched the NCBI PubMed database for publications from which a list of cancer hallmark genes could be extracted or reconstructed. Then, we performed a cancer hallmarks enrichment analysis on a list of differentially expressed genes between normal and tumor tissues across eleven solid tumor types.
Results
Consolidating hallmark genes from seven projects, we identified 6,763 genes associated with ten cancer hallmarks. We discovered a hallmark enrichment “fingerprint” specific to each tumor type. Notably, kidney cancers displayed the most extensive hallmark enrichment, underscoring the complexity of the disease. Hallmarks linked to immune function, such as “Evading immune destruction” and “Tumor promoting inflammation” were prominently enriched in kidney and CNS cancers (p<0.0001). “Tissue invasion and metastasis” was the single most prominent hallmark in skin and pancreatic cancers (p<0.0001), known to metastasize early. "Reprogramming energy metabolism" emerged as the hallmark particularly enriched in breast, ovarian, and uterine cancers (p<0.0001), suggesting the feasibility of metabolic approaches to target these cancers. The hallmark “Genome instability” was significantly enriched in cancers frequently associated with lifestyle choices, including colon, oesophageal, and liver cancers (p<0.05), and in cervical cancers, known to be linked to HPV infection (p<0.0001). To facilitate the analysis of cancer hallmarks, we developed an online tool (www.cancerhallmarks.com) to identify cancer-associated hallmarks from novel gene sets.
Conclusions
We established a consensus list of cancer hallmark genes and delineated unique patterns of hallmark enrichment across diverse tumors. Our findings hold potential pharmacological implications and enhance the utility of the hallmark concept as an effective organizational tool.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This project was supported by the National Research, Development, and Innovation Office (PharmaLab, RRF-2.3.1-21-2022-00015) in Hungary. O.M. was supported by the Janos Bolyai Scholarship of the Hungarian Academy of Sciences and the Hungarian Scientific Research Fund (OTKA FK147194). The support of ELIXIR Hungary (www.bioinformatics.hu) is acknowledged.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1812TiP - IDeate-Lung03: A Phase Ib/II study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first-line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC)
Presenter: Charles Rudin
Session: Poster session 07
1813TiP - Debio 0123, a highly selective WEE1 inhibitor, combined with carboplatin (CP) and etoposide (ETOP) in patients (pts) with small cell lung cancer (SCLC) that progressed after platinum-based therapy: A phase I dose escalation and expansion study
Presenter: Valentina Gambardella
Session: Poster session 07
2P - Single-cell profiling and integrative TCR analysis reveals tumor-mutation associated phenotypes and immune repertoire in lung adenocarcinoma
Presenter: Alexander Lozano
Session: Poster session 07
3P - Metabolic reprogramming induced by KEAP1 mutation in NSCLC
Presenter: Renata Akhmetzianova
Session: Poster session 07
4P - CBL-B inhibition overcomes PD-1/LAG-3 mediated resistance in lung cancer
Presenter: Luisa Chocarro
Session: Poster session 07
5P - Circulating tumor cell-derived organoids from lung adenocarcinoma patients for assessment of EGFR and KRAS mutations
Presenter: Mohamed Lahmadi
Session: Poster session 07
6P - Circulating low-density neutrophils (LDNs) are associated with resistance to immunotherapy as frontline treatment for non-small cell lung cancer (NSCLC): Updated results and proteomic characterization
Presenter: Natalia Castro Unanua
Session: Poster session 07
7P - Association study between genetic variants in regulatory gene for RNA modification and prognosis in non-small cell lung cancer
Presenter: Eungbae Lee
Session: Poster session 07
8P - Profiling of zidesamtinib and other ROS1 inhibitors in an intracranial CD74-ROS1 G2032R preclinical model
Presenter: ANUPONG TANGPEERACHAIKUL
Session: Poster session 07
9P - Small-extracellular vesicles derived from NSCLC cells dampen the CD8+ T cell response against tumor
Presenter: Manon CHANG
Session: Poster session 07